{"article_title": "Can Gilead Double From Here?", "article_keywords": ["gilead", "double"], "article_url": "http://www.forbes.com/sites/kenkam/2014/11/14/can-gilead-double-from-here/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Ken Kam", "og": {"site_name": "Forbes", "description": "Investors in Gilead Sciences (NASDAQ: GILD) have seen their investments grow 35% per year for the past five years, and 58% over the last 12 months. Since our conversation about Gilead with Eugene Groysman in June, the stock has appreciated 29%. After a stock has done this well, it is only natural to ask whether it can keep going, or whether it\u2019s time to sell. To answer that question, I talked to 2 Marketocracy Masters, Eugene Groysman and Mike Koza, to discuss whether Gilead can double again.", "title": "Can Gilead Double From Here?", "url": "http://www.forbes.com/sites/kenkam/2014/11/14/can-gilead-double-from-here/", "image": "http://blogs-images.forbes.com/kenkam/files/2014/11/bigstock-health-care-professionals-in-l-62512976-1940x129321-e1415899666742111112111.jpg", "updated_time": "2014-11-14T10:23:18-05:00", "type": "article"}, "twitter": {"description": "Investors in Gilead Sciences (NASDAQ: GILD) have seen their investments grow 35% per year for the past five years, and 58% over the last 12 months. Since our conversation about Gilead with Eugene Groysman in June, the stock has appreciated 29%. After a stock has done this well, it is only natural to ask whether it can keep going, or whether it\u2019s time to sell. To answer that question, I talked to 2 Marketocracy Masters, Eugene Groysman and Mike Koza, to discuss whether Gilead can double again.", "creator": "@http://twitter.com/MarketocracyInc", "image": "http://blogs-images.forbes.com/kenkam/files/2014/11/bigstock-health-care-professionals-in-l-62512976-1940x129321-e1415899666742111112111.jpg", "title": "Can Gilead Double From Here?", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Advisor Network,Health,Intelligent Investing,Investing,Lifestyle,Markets,Pharma and Health,Powering Productivity,Wall Street,healthcare,Pharma &amp; Healthcare", "article": {"publisher": "https://www.facebook.com/forbes", "author": "http://www.facebook.com/https://www.facebook.com/Marketocracy", "section_url": "http://www.forbes.com/powering-productivity", "section": "Powering Productivity", "modified": "2014-11-14", "published": "2014-11-14", "id": "blogAndPostId/blog/post/1681-2154"}, "news_keywords": "Advisor Network,Health,Intelligent Investing,Investing,Lifestyle,Markets,Pharma and Health,Powering Productivity,Wall Street,healthcare,Pharma &amp; Healthcare", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "Investors in Gilead Sciences (NASDAQ: GILD) have seen their investments grow 35% per year for the past five years, and 58% over the last 12 months. Since our conversation about Gilead with Eugene Groysman in June, the stock has appreciated 29%. After a stock has done this well, it is only natural to ask whether it can keep going, or whether it\u2019s time to sell. To answer that question, I talked to 2 Marketocracy Masters, Eugene Groysman and Mike Koza, to discuss whether Gilead can double again."}, "_id": "\"57477af46914bd0286fdd526\"", "article_summary": ""}